Track topics on Twitter Track topics that are important to you
The objective of the IDEaL Registry is to allow physicians, scientists, and patients the opportunity to obtain an overall profile of real-world "effectiveness" data associated with Ig therapy.
This is a prospective, longitudinal, observational registry study to provide a unique and effective mechanism to acquire real-world data on product prescribing, product use by patients, and product performance for patients receiving Ig therapy (IVIg and SCIg) in a homecare and/or ambulatory infusion setting, regardless of disease treated. There is no limit on the number of people that may participate in the registry. The IDEaL Registry will be overseen by a single Principal Investigator. Coram estimates that approximately 40 sites in the US will participate as submitting centers in this registry, but there will be no limit to this number. Any and all patients being treated with Ig therapy who have not yet begun to use Coram's home and/or ambulatory infusion services will be invited to participate in this study.
Participation in the registry will continue as long as the subject is:
- Being treated with Ig replacement therapy (this does not include monoclonal antibody therapy),
- Using Coram's home and/or ambulatory infusion services,
- Willing to participate in this registry, and
- Until the Sponsor or Principal Investigator decide to terminate their participation in the IDEaL Registry.
The data entry for this study differs from other registries in that the data that is going into the registry is being collected by the homecare agency (pharmacy and nurses). The data collected for the IDEaL Registry will be collected on the standard Physician Order, Nursing Records, etc. Copies of these are sent to the study doctors for their standard patient medical records, as is standard for the homecare approach. For the IDEaL Registry, data routinely entered into Coram's database will be processed in the same manner as for non-registry patients, but will be extracted in a systematic fashion for incorporation into the IDEaL Registry. The other standard forms, and the Registry-specific Quality of Life Questionnaire form will also be sent to Coram to be entered into the IDEaL Registry.
Observational Model: Cohort, Time Perspective: Prospective
IVIg and SCIg Therapy in the Home or at an Alternate Site
Coram Clinical Trials
Published on BioPortfolio: 2014-08-27T03:14:12-0400
Tolerability of home subcutaneous immunoglobulin (ScIG) for replacement therapy for hypogammaglobulinemia in allogeneic HCT patients. A financial analysis comparing the cost of ScIG with i...
The aim of this study is to evaluate development of hemolysis and the variation in isokinetic muscle strength in two groups of patients with chronic inflammatory demyelinating polyneuropat...
Most immunodeficiencies are related to severe immunoglobulin deficiencies which require lifelong replacement therapy with immunoglobulin G (IgG) to reduce the incidence and severity of inf...
To determine whether high-dose intravenous immunoglobulin (IVIg) is more effective than placebo in restoring lost visual function (visual acuity) in optic neuritis (ON). To determine the ...
Inflammatory cytokines in the cerebrospinal fluid may contribute to the new muscle weakness, fatigue and pain experienced by patients with post-polio syndrome. Intravenousimmunoglobulin (I...
CIDP patients treated with intravenous immunoglobulin (IVIg) usually start with a standard dosage of 2 g/kg body weight. Only a minority of patients have a sustained improvement, and most require ongo...
For decades, intravenous immunoglobulin (IVIg) has provided safe and effective therapy for immunodeficient patients. This proof-of-principle study describes a novel approach to generate personalized I...
Variation of muscle strength and function have not been studied in patients with chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy whose treatment regimen has been chan...
A randomized, multicentre phase III study of three different doses of intravenous immunoglobulin 10% in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ProCID trial): Study design and protocol.
Patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) show varying degrees of response to intravenous immunoglobulin (IVIg) therapy. This randomised phase III study in patient...
Rituximab and intravenous immunoglobulin [IVIg] have recently emerged as effective treatments for pemphigus refractory to corticosteroids [CS]. This case series sought to compare the clinical, serolog...
Use of any infusion therapy on an ambulatory, outpatient, or other non-institutionalized basis.
Nursing care given to an individual in the home. The care may be provided by a family member or a friend. Home nursing as care by a non-professional is differentiated from HOME CARE SERVICES provided by professionals: visiting nurse, home health agencies, hospital, or other organized community group.
Hospital-sponsored provision of health services, such as nursing, therapy, and health-related homemaker or social services, in the patient's home. (Hospital Administration Terminology, 2d ed)
A nursing specialty in which skilled nursing care is provided to patients in their homes by registered or licensed practical NURSES. Home health nursing differs from HOME NURSING in that home health nurses are licensed professionals, while home nursing involves non-professional caregivers.
Public or private organizations that provide, either directly or through arrangements with other organizations, home health services in the patient's home. (Hospital Administration Terminology, 2d ed)
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...